BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Elusys Therapeutics, Inc. 

25 Riverside Drive
P.O. Box 102
Pine Brook  New Jersey  07058  U.S.A.
Phone: 973-808-0222 Fax: 973-808-0322


SEARCH JOBS


Industry
Biotechnology






 Company News
Elusys Therapeutics, Inc. Completes Commercial Manufacturing Process Validation For Anthrax Antitoxin ETI-204 4/9/2014 8:38:10 AM    More...
Elusys Therapeutics, Inc. Completes Enrollment In Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, ETI-204, In Adult Volunteers 2/5/2014 8:20:07 AM    More...
Elusys Therapeutics, Inc. Releases New Data on Anthrax Anti-Toxin Administered Via Intramuscular Injection From Three Recent Animal Studies 8/1/2013 8:58:55 AM    More...
Alliance for Biosecurity Elects Chief Executive Officers of Bavarian Nordic (BAVA.CO) and Elusys Therapeutics, Inc. as New Co-Chairs 7/1/2013 8:17:59 AM    More...
Elusys Therapeutics, Inc. Awarded Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational Anthrax 9/17/2012 10:01:20 AM    More...
Elusys Therapeutics, Inc. Receives Additional $14.5 Million Funding From U.S. Govt. to Support Expanded Human Safety Studies of ETI-204 9/17/2012 7:12:49 AM    More...
Elusys Therapeutics, Inc. Gets $50.2 Million to Advance Investigational Anthrax Treatment 8/3/2012 8:05:55 AM    More...
Elusys Therapeutics, Inc. Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale 10/24/2011 2:27:09 PM    More...
Elusys Therapeutics, Inc. Awarded $68 Million Contract to Develop Anthim for Intramuscular Pre- and Post-Exposure Prophylaxis of Anthrax Infection 9/8/2011 8:05:33 AM    More...
Elusys Therapeutics, Inc. Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax 8/4/2010 11:24:45 AM    More...
1234

//-->